Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Read more about Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case-Control Consortium (PanC4). Read more about Dietary acrylamide and the risk of pancreatic cancer in the International Pancreatic Cancer Case-Control Consortium (PanC4).
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Read more about 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches. Read more about Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer. Read more about Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Read more about Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. Read more about A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Read more about What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Read more about CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Read more about Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
